GlassScriptPhysician profile
Shaline Rao
NPI 1174724827
$120,004.15
in general payments reported to CMS, 2019-2025
32 companies · $21K in 2025
The $21K reported for 2025 was more than what 85% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $7,850 · 2021: $15K · 2022: $26K · 2023: $26K · 2024: $23K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Consulting Fee: $8,108 · Food and Beverage: $2,903 · Travel and Lodging: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,067.50 |
| Consulting Fee | $8,107.50 |
| Food and Beverage | $2,903.15 |
| Travel and Lodging | $2,467.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72,911.16 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $16,793.98 | 2019-2025 | Amvuttra |
| Novo Nordisk INC | $6,238.65 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pharmacosmos Therapeutics INC. | $3,785.00 | 2021 | |
| Eli Lilly and Company | $3,520.00 | 2022 | |
| Lilly USA, LLC | $3,300.00 | 2022-2024 | Jardiance |
| C. R. Bard, INC. & Subsidiaries | $2,972.12 | 2020 | |
| Abbott Laboratories | $2,517.58 | 2019-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Akcea Therapeutics, INC. | $2,292.44 | 2020 | |
| Medtronic, INC. | $1,509.17 | 2019-2023 | |
| Vifor (International) LTD. | $1,041.66 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,006.90 | 2021-2025 | Wainua, Farxiga |
| Pfizer INC. | $750.72 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $225.35 | 2019-2022 | |
| Cvrx, INC. | $199.52 | 2022-2024 | Barostim Neo System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.22 | 2021-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $113.78 | 2021-2023 | Verquvo |
| Daxor Corporation | $101.56 | 2024 | Bva-100 |
| E.R. Squibb & Sons, L.L.C. | $96.26 | 2022-2023 | Camzyos |
| Vifor Pharma, INC. | $73.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $66.69 | 2021-2023 | Xarelto |
| Bridgebio Pharma, INC. | $58.43 | 2025 | Attruby |
| Amgen INC. | $53.06 | 2019-2024 | Repatha |
| Scpharmaceuticals INC. | $50.23 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $43.46 | 2019 | |
| Endotronix, INC. | $36.10 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Impulse Dynamics (USA) INC. | $24.73 | 2022 | |
| Daiichi Sankyo INC. | $21.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2022 | |
| Sensible Medical Innovations INC | $15.73 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.33 | 2023 | Inpefa |
| Gilead Sciences, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaline Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.